摘要
目的对比观察普罗帕酮、胺碘酮、倍他乐克治疗阵发性室上性心动过速的临床疗效和安全性并提出护理措施。方法将112例阵发性室上性心动过速患者随机分为普罗帕酮组、胺碘酮组、倍他乐克组。对比3组患者的转复率、转复时间和不良反应发生率。结果普罗帕酮组转复率较胺碘酮组高(P<0.05);普罗帕酮组与倍他乐克组转复时间少于胺碘酮组(P<0.05);不良反应发生率3组无显著性差异,但普罗帕酮组的不良反应较重。结论胺碘酮和倍他乐克均能有效、安全地终止阵发性室上性心动过速,同时正确而有效的护理对提高转复率、降低不良反应发生率有一定作用。
Objective To compare the observation of propafenone,amiodarone,metoprolol treatment of paroxysmal supraventricular tachycardia in the clinical efficacy and safety of care measures put forward.Methods 112 patients with paroxysmal supraventricular tachycardia were randomly divided into the propafenone group,amiodarone group and metoprolol group.Compared three groups of patients with cardioversion rate of cardioversion of time and the incidence of adverse reactions.Results Propafenone group cardioversion rate higher than the amiodarone group（P0.05）;Propafenone group and metoprolol group cardioversion less than amiodarone group（P0.05）;Adverse reaction rates three There was no significant difference,but the heavier side effects propafenone group.Conclusion Amiodarone and metoprolol were effective and safe termination of paroxysmal supraventricular tachycardia,while the correct and effective transfer of care to improve recovery rates and reduce the incidence of adverse reactions have a certain effect.
出处
《中外医疗》
2011年第17期13-14,16,共3页
China & Foreign Medical Treatment
